#RNL2024 @RheumNow @_AprilArmstrong Bimekizumab: IL-17A and IL-17F dual efficacy, unlike the prior IL-17i drugs - Fast onset - High efficacy with 2/3 PASI 100 by wk 16 (BE READY) https://t.co/cKh7j4KBs9